Dra. Cristina Saura

Dra. Cristina Saura

Dr. Cristina Saura is the Head of the Breast Cancer Unit of the Service of Medical Oncology of Vall d’Hebron University Hospital, and Principal Investigator of VHIO’s research group on Breast Cancer and Melanoma since September 2015. 

Dr. Saura has participated as Principal Investigator and co-investigator in multiple clinical trials in the field of research on breast cancer driven by her interest in the development of new drugs that improve the prognosis of patients. She is currently involved in different international studies with drugs targeted against molecular targets in breast cancer.

The work of dr. Saura is focused on precision medicine and she occupies a prominent position in the development of PI3K inhibitors and new anti-HER2 treatments. In the field of pregnancy-related breast cancer, she is currently leading a project on early diagnosis of breast cancer based on the presence of circulating DNA in breast milk. 

  • Head of the Breast Cancer Unit, Vall d’Hebron University Hospital, Barcelona, Spain.
  • Principal Investigator of the Breast Cancer Group, Vall d’Hebron Institute of Oncology/VHIO.


  • Graduated in Medicine from the University of Barcelona (UB) in 2002. 
  • Internship in Medical Oncology at Vall d’Hebron Hospital in Barcelona from 2003 to 2007.
  • Master in Advanced Studies and Research Aptitude. with the project “Breast Cancer Early Detection Program in High-Risk Women: pilot breast mammography and breast magnetic resonance imaging tracking experience”, with an outstanding grade “A”.
  • Program in Clinical Effectiveness at Harvard School of Public Health in Boston in 2007.
  • PhD in Medicine from the Universtat Autonoma of Barcelona (UAB) in 2017 with honors cum laude with the project entitled «Treatment of breast cancer diagnosed during pregnancy».


  • Grant of the Strategic Plan for Research and Innovation in Health (PERIS) from the Generalitat de Catalunya in 2018 with the project «Precision medicine in metastatic breast cancer: determination of mutations in tumors and circulating DNA as a guide for the treatment of patients with metastatic breast cancer».
  • Member of the Scientific Committee and Board of Directors of the cooperative breast cancer group SOLTI. 
  • Member of the Spanish Society of Medical Oncology (SEOM)
  • Member of GEICAM (Spanish Breast Cancer Research Group) and the European and American Oncology Societies (ESMO, ASCO).


Author of multiple publications, as well as communications at different national and international congresses.

No Comments

Sorry, the comment form is closed at this time.